Avanos Medical Inc (NYSE:AVNS) Surpasses Q2 2025 Earnings and Revenue Estimates

Avanos Medical Inc (NYSE:AVNS) reported its second-quarter 2025 financial results, surpassing analyst expectations on both revenue and earnings per share (EPS). The medical technology company posted revenue of $175 million, exceeding the consensus estimate of $168.81 million. Adjusted EPS came in at $0.17, beating the forecasted $0.153.

Key Financial Highlights

• Revenue Growth: The company reported $175 million in Q2 sales, a 3.7% increase over analyst expectations.
• Profitability: EPS of $0.17 outperformed estimates by 11.1%, reflecting improved operational execution.
• Market Reaction: Shares rose 11.56% in pre-market trading, indicating strong investor optimism following the earnings beat.

Business Performance & Outlook

CEO David Pacitti highlighted strength in the Specialty Nutrition Systems segment, which supports patient nutrition from hospital to home, as well as progress in the Pain Management & Recovery segment, which focuses on opioid-sparing solutions. The company expressed confidence in meeting its full-year 2025 financial guidance, though no specific numerical outlook was provided in the press release.

Analysts currently project full-year 2025 revenue at $685.44 million and EPS at $0.87. For Q3, estimates stand at $170.85 million in sales and $0.184 EPS.

Leadership Update

In a separate announcement, Avanos appointed Scott Galovan as its new Chief Financial Officer, effective August 1, 2025. Additionally, David Pacitti was appointed to the company’s board of directors. These leadership changes may signal strategic shifts as the company continues its transformation efforts.

Market Sentiment & Recent Performance

Despite the positive earnings reaction, Avanos’ stock has seen mixed performance in recent weeks:

• Last Week: -0.06%
• Last Two Weeks: -0.01%
• Last Month: -0.05%

The sharp pre-market rally suggests that investors are rewarding the earnings beat, though broader market conditions and future execution will determine whether this momentum holds.

For a deeper dive into Avanos Medical’s earnings and analyst estimates, visit the earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.